文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

全球癌症免疫治疗中 B7-H3 的研究趋势:文献计量分析(2012-2022 年)。

Global research trends on B7-H3 for cancer immunotherapy: A bibliometric analysis (2012-2022).

机构信息

Department of Oncology, Qingdao Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao, China.

出版信息

Hum Vaccin Immunother. 2023 Aug 1;19(2):2246498. doi: 10.1080/21645515.2023.2246498.


DOI:10.1080/21645515.2023.2246498
PMID:37635349
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10464541/
Abstract

Immunotherapy has revolutionized cancer treatment. B7-H3 is a promising target for cancer immunotherapy (CI). The present study aimed to utilize bibliometric methods to assess the current research status and explore future trends in the use of B7-H3 for CI. We collected publications related to B7-H3/CI from the Clarivate Web of Science Core Collection database. VOSviewer, Microsoft Excel, the bibliometrix R package, and an online platform were used to conduct qualitative and visualized analyses of the literature. A total of 555 papers were analyzed, revealing a significant increase in annual publications since 2018. The most productive countries were China and the USA, and the leading institutions were Soochow University and Sichuan University. Zang and Ferrone were the most popular authors. Among the journals, had the highest number of papers, whereas was the most influential. Historical citation analysis reveals the development of B7-H3/CI. Top-cited papers and keyword analyses were performed to highlight current hotspots in the domain. Using cluster analysis, we classified all keywords into four clusters: "immunotherapy," "co-stimulatory molecule," "B7 family," and "PD-L1." Finally, Trends analysis suggested that future research might focus on "chimeric antigen receptor," "pathways," and "targeting B7-H3." This is the first bibliometric crosstalk analysis between B7-H3 and CI. Our study illustrates that the topic of B7-H3/CI is very popular and has great clinical implications and that the number of correlative publications will continue to increase. B7-H3-based CI may lead to new research trends.

摘要

免疫疗法已经彻底改变了癌症治疗。B7-H3 是癌症免疫治疗 (CI) 的一个有前途的靶点。本研究旨在利用文献计量学方法评估 B7-H3 用于 CI 的当前研究现状并探索未来趋势。我们从科睿唯安 Web of Science 核心合集数据库中收集了与 B7-H3/CI 相关的出版物。使用 VOSviewer、Microsoft Excel、bibliometrix R 包和在线平台对文献进行定性和可视化分析。共分析了 555 篇论文,显示自 2018 年以来年度出版物数量显著增加。最具生产力的国家是中国和美国,领先的机构是苏州大学和四川大学。Zang 和 Ferrone 是最受欢迎的作者。在期刊中, 发表的论文数量最多,而 是最有影响力的期刊。历史引文分析揭示了 B7-H3/CI 的发展。对高被引论文和关键词分析突出了该领域的当前热点。使用聚类分析,我们将所有关键词分为四个聚类:“免疫疗法”、“共刺激分子”、“B7 家族”和“PD-L1”。最后,趋势分析表明,未来的研究可能集中在“嵌合抗原受体”、“途径”和“靶向 B7-H3”上。这是 B7-H3 和 CI 之间的首次文献计量交叉分析。我们的研究表明,B7-H3/CI 主题非常热门,具有重要的临床意义,相关出版物的数量将继续增加。基于 B7-H3 的 CI 可能会带来新的研究趋势。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6804/10464541/8b7db6d4bde1/KHVI_A_2246498_F0007_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6804/10464541/323c7aedeff3/KHVI_A_2246498_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6804/10464541/74a682657d1b/KHVI_A_2246498_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6804/10464541/da9f4e8f2206/KHVI_A_2246498_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6804/10464541/995a96e390ac/KHVI_A_2246498_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6804/10464541/b66b44668157/KHVI_A_2246498_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6804/10464541/cb6cb4146794/KHVI_A_2246498_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6804/10464541/8b7db6d4bde1/KHVI_A_2246498_F0007_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6804/10464541/323c7aedeff3/KHVI_A_2246498_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6804/10464541/74a682657d1b/KHVI_A_2246498_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6804/10464541/da9f4e8f2206/KHVI_A_2246498_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6804/10464541/995a96e390ac/KHVI_A_2246498_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6804/10464541/b66b44668157/KHVI_A_2246498_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6804/10464541/cb6cb4146794/KHVI_A_2246498_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6804/10464541/8b7db6d4bde1/KHVI_A_2246498_F0007_OC.jpg

相似文献

[1]
Global research trends on B7-H3 for cancer immunotherapy: A bibliometric analysis (2012-2022).

Hum Vaccin Immunother. 2023-8-1

[2]
Global research trends on the links between gut microbiota and cancer immunotherapy: A bibliometric analysis (2012-2021).

Front Immunol. 2022

[3]
Knowledge mapping and current trends of immunotherapy for prostate cancer: A bibliometric study.

Front Immunol. 2022

[4]
Worldwide productivity and research trend of publications concerning tumor immune microenvironment (TIME): a bibliometric study.

Eur J Med Res. 2023-7-10

[5]
Bibliometric Analysis of Chimeric Antigen Receptor-Based Immunotherapy in Cancers From 2001 to 2021.

Front Immunol. 2022

[6]
Global research trends in immunotherapy for glioma: a comprehensive visualization and bibliometric analysis.

Front Endocrinol (Lausanne). 2023

[7]
Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis.

Front Oncol. 2022-11-17

[8]
Emerging trends and research foci of oncolytic virotherapy for central nervous system tumors: A bibliometric study.

Front Immunol. 2022

[9]
Research Trends in the Application of Artificial Intelligence in Oncology: A Bibliometric and Network Visualization Study.

Front Biosci (Landmark Ed). 2022-8-31

[10]
Bibliometric and visualized analysis of the top-100 highly cited articles on immunotherapy for endometrial cancer.

Medicine (Baltimore). 2023-7-7

引用本文的文献

[1]
Radiomic features based on pyradiomics predict CD276 expression associated with breast cancer prognosis.

Heliyon. 2024-9-3

[2]
Current status and future directions of nanovaccine for cancer: a bibliometric analysis during 2004-2023.

Front Immunol. 2024

本文引用的文献

[1]
Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy.

J Hematol Oncol. 2022-10-25

[2]
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial.

J Immunother Cancer. 2022-4

[3]
Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy.

Immune Netw. 2022-2-14

[4]
Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis.

Eur Urol. 2022-4

[5]
Molecular basis of C-mannosylation - a structural perspective.

FEBS J. 2022-12

[6]
The role of B7-H3 in tumors and its potential in clinical application.

Int Immunopharmacol. 2021-12

[7]
B7-H3/CD276: An Emerging Cancer Immunotherapy.

Front Immunol. 2021

[8]
FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer.

Nat Commun. 2021-5-11

[9]
Expression, regulation and clinical significance of B7-H3 on neutrophils in human gastric cancer.

Clin Immunol. 2021-6

[10]
CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance.

Cell Stem Cell. 2021-9-2

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索